Live price temporarily unavailable.
Agenus (AGEN) is a Health Care company in the Russell 2000. Latest news and coverage below.
Agenus revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $22.6M | $42.9M | $36.8M | $150.0M | $88.2M | $295.7M | $98.0M | $156.3M | $103.5M | $114.2M |
| Growth (year over year) | −9.0% | +89.9% | −14.2% | +307.9% | −41.2% | +235.3% | −66.8% | +59.5% | −33.8% | +10.4% |
| Gross profit | — | — | — | — | $85.8M | $292.2M | $87.5M | $153.2M | $103.0M | $113.2M |
| Gross margin | — | — | — | — | 97.3% | 98.8% | 89.2% | 98.0% | 99.5% | 99.1% |
| Operating income | −$107.5M | −$103.8M | −$123.8M | −$70.1M | −$117.2M | $25.7M | −$179.4M | −$159.5M | −$120.5M | −$20.2M |
| Operating margin | −476.1% | −242.1% | −336.6% | −46.7% | −133.0% | 8.7% | −183.0% | −102.1% | −116.4% | −17.7% |
| Net income | −$127.0M | −$120.7M | −$159.9M | −$107.9M | −$181.1M | −$24.1M | −$220.3M | −$246.0M | −$227.4M | −$101.0K |
| Net margin | −562.6% | −281.5% | −434.7% | −71.9% | −205.4% | −8.2% | −224.7% | −157.4% | −219.8% | −0.1% |
| EPS (diluted) | −$584.00 | −$492.00 | −$576.00 | −$320.00 | −$21.00 | −$2.20 | −$15.64 | −$13.75 | −$10.59 | $0.00 |
| Balance sheet | ||||||||||
| Cash and equivalents | $71.4M | $60.2M | $53.1M | $61.8M | $99.9M | $291.9M | $178.7M | $76.1M | $40.4M | $3.00M |
| Total assets | $157.0M | $138.4M | $136.4M | $155.3M | $214.5M | $466.0M | $413.6M | $313.9M | $226.3M | $226.8M |
| Total liabilities | $196.1M | $214.2M | $310.9M | $386.7M | $426.0M | $418.0M | $468.5M | $462.3M | $532.7M | $504.7M |
| Long-term debt | $130.5M | $142.4M | $13.2M | $13.4M | $18.9M | $12.8M | $12.6M | $12.8M | $30.5M | $0 |
| Shareholders' equity | −$39.1M | −$75.8M | −$172.5M | −$225.4M | −$203.7M | $34.4M | −$61.3M | −$160.3M | −$326.4M | −$271.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$80.0M | −$94.2M | −$131.1M | −$18.7M | −$139.1M | $10.1M | −$175.4M | −$224.2M | −$158.3M | −$77.2M |
| Capital expenditure | $12.5M | $3.12M | $3.60M | $4.66M | $3.47M | $33.8M | $53.1M | $9.95M | $576.0K | $6.00K |
| Free cash flow | −$92.5M | −$97.3M | −$134.7M | −$23.3M | −$142.6M | −$23.7M | −$228.4M | −$234.2M | −$158.9M | −$77.2M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $25.1M | $26.8M | $24.1M | $25.7M | $30.2M | $34.2M | $33.7M | $34.5M |
| Growth (year over year) | +3.3% | — | −14.1% | +9.3% | +20.4% | +27.5% | +40.2% | +34.4% |
| Gross profit | $25.0M | $26.7M | $23.9M | $25.4M | $29.6M | $34.2M | $33.7M | $34.5M |
| Gross margin | 99.4% | 99.6% | 99.4% | 99.1% | 97.9% | 100.0% | 100.0% | 100.0% |
| Operating income | −$31.5M | −$25.9M | −$13.3M | −$16.7M | −$4.54M | $14.4M | $15.1M | $11.3M |
| Operating margin | −125.5% | −96.5% | −55.3% | −65.0% | −15.0% | 42.1% | 44.6% | 32.7% |
| Net income | −$66.4M | −$45.9M | −$25.3M | −$28.0M | $63.9M | −$10.6M | $39.2M | −$604.0K |
| Net margin | −264.6% | −171.1% | −105.2% | −109.0% | 211.2% | −31.1% | 116.1% | −1.7% |
| EPS (diluted) | −$3.08 | −$1.95 | −$1.03 | −$1.00 | $1.94 | $0.09 | $1.02 | −$0.01 |
| Balance sheet | ||||||||
| Cash and equivalents | $44.8M | $40.4M | $18.5M | $9.53M | $3.46M | $3.00M | $35.0M | $18.7M |
| Total assets | $238.5M | $226.3M | $200.2M | $185.2M | $233.9M | $226.8M | $186.5M | $172.7M |
| Total liabilities | $510.3M | $532.7M | $522.6M | $521.5M | $514.8M | $504.7M | $414.4M | $378.5M |
| Long-term debt | $0 | $30.5M | $32.8M | $23.2M | $23.6M | $0 | $30.2M | $30.1M |
| Shareholders' equity | −$292.3M | −$326.4M | −$341.8M | −$354.6M | −$274.1M | −$271.1M | −$221.2M | −$199.1M |
| Cash flow | ||||||||
| Operating cash flow | −$53.3M | −$28.7M | −$25.6M | −$20.2M | −$14.7M | −$16.6M | −$36.0M | −$31.2M |
| Capital expenditure | $7.00K | $73.0K | $5.00K | $1.00K | $0 | $0 | $0 | $0 |
| Free cash flow | −$53.3M | −$28.7M | −$25.6M | −$20.2M | −$14.7M | −$16.6M | −$36.0M | −$31.2M |
From Agenus's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Agenus
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
- Headquarters
- Lexington, Massachusetts From SEC filings, Oct 2026
Recent News
No recent news mentioning Agenus in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International